“…Immunocompromised patients are at risk of developing hyperinfection syndrome and disseminated strongyloidiasis that can be fatal, mostly due to Gram-negative bacteremia and sepsis [ 3 , 4 ]. Severe strongyloidiasis typically follows corticosteroid therapy, but has also been described in patients with lymphoma, leukemia, human T-cell lymphotropic virus (HTLV) and HIV infection, malnutrition, chronic renal failure and end-stage renal disease, alcoholism, diabetes mellitus, advanced age, and in solid organ transplant recipients [ 2 , 3 , 4 , 5 , 6 , 7 , 8 ]. Therefore, it is mandatory to diagnose and treat chronic carriers, in order to prevent the hyperinfection syndrome if immunosuppressive treatment is planned [ 3 , 4 , 5 , 6 , 7 , 8 ].…”